The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary

Gynecologic Oncology

Volumn 110, Issue 2, 2008, Pages 125-132

  Kumar, Sanjeev ^a,b   Shah, Jay P ^a,b   Bryant, Christopher S ^a,b   Imudia, Anthony N ^a,b   Cote, Michele L ^a,b   Ali fehmi, Rouba ^a,b   Malone Jr , John M ^a,b   Morris, Robert T ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Histology; Lymph nodes; Malignant germ cell tumors; Metastasis; Ovary

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHILD; DYSGERMINOMA; FEMALE; FISHER EXACT TEST; HISTOLOGY; HUMAN; HUMAN TISSUE; INFANT; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALIGNANT OVARIAN GERM CELL TUMOR; MALIGNANT TERATOMA; MULTIVARIATE ANALYSIS; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RACE DIFFERENCE; STATISTICAL ANALYSIS; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; PREVALENCE; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 47249126694     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.04.022     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Talerman A. Germ cell tumors of the ovary. Curr Opin Obstet Gynecol 9 (1997) 44-47
3. Tewari K., Cappuccini F., Disaia P.J., Berman M.L., Manetta A., and Kohler M.F. Malignant germ cell tumors of the ovary. Obstet Gynecol 95 (2000) 128-133
4. Norris H.J., and Jensen R.D. Relative frequency of ovarian neoplasms in children and adolescents. Cancer 30 (1972) 713-719
5. Gershenson D.M. Management of ovarian germ cell tumors. J Clin Oncol 25 (2007) 2938-2943
6. Roth L.M., and Talerman A. Recent advances in the pathology and classification of ovarian germ cell tumors. Int J Gynecol Pathol 25 (2006) 305-320
7. Frederick L., Greene D.L.P., Fleming ID., Fritz A., Balch C.M., Haller D.G., and Morrow M. AJCC Cancer Staging Manual 6th Edition. 6th ed (2002), Springer May 10, 2002
8. Edwin M., and Posadas E.C.K. Tumor angiogenesis and metastasis: biology and clinical experience. In: Hoskins W.J. (Ed). Principles and Practice of Gynecologic Oncology. Fourth (2005), Lippincott Williams & Wilkins 73-91
9. Onda T., Yoshikawa H., Yokota H., Yasugi T., and Taketani Y. Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy. Cancer 78 (1996) 803-808
10. Matei D.E. Ovarian germ-cell tumors. In: Hoskins W.J. (Ed). Principles and Practice of Gynecologic Oncology. Fourth (2005), Lippincott Williams & Wilkins 989-1009
11. *Stat Database: Incidence - SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying) - Linked To County Attributes - Total U.S., 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission. In.
12. Smith H.O., Berwick M., Verschraegen C.F., Wiggins C., Lansing L., Muller C.Y., et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 107 (2006) 1075-1085
13. Ries L., and Fritz A. SEER Extent of disease-1988. Third edition (1998), National Cancer Institute NIH
14. Seiffert JE. SEER Program: comparative staging guide for cancer version 1.1: National Cancer Institue, NIH.
15. Morice P., Joulie F., Camatte S., Atallah D., Rouzier R., Pautier P., et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 197 (2003) 198-205
16. Fidler I.J. Critical determinants of metastasis. Semin Cancer Biol 12 (2002) 89-96
17. Gershenson D.M., Del Junco G., Copeland L.J., and Rutledge F.N. Mixed germ cell tumors of the ovary. Obstet Gynecol 64 (1984) 200-206
18. Burghardt E., Girardi F., Lahousen M., Tamussino K., and Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 40 (1991) 103-106
19. Benedetti-Panici P., Greggi S., Maneschi F., Scambia G., Amoroso M., Rabitti C., et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol 51 (1993) 150-154
20. di Re F., Baiocchi G., Fontanelli R., Grosso G., Cobellis L., Raspagliesi F., et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovariancancer: prognostic significance of node metastases. Gynecol Oncol 62 (1996) 360-365
21. Ayhan A., Gultekin M., Celik N.Y., Dursun P., Taskiran C., Aksan G., et al. Occult metastasis in early ovarian cancers: risk factors and associated prognosis. Am J Obstet Gynecol 196 81 (2007) e1-e6
22. Vernooij F., Heintz P., Witteveen E., and van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 105 (2007) 801-812
23. Kohler C., Klemm P., Schau A., Possover M., Krause N., Tozzi R., et al. Introduction of transperitoneal lymphadenectomy in a gynecologic oncology center: analysis of 650 laparoscopic pelvic and/or paraaortic transperitoneal lymphadenectomies. Gynecol Oncol 95 (2004) 52-61
24. Schlatter M., Rescorla F., Giller R., Cushing B., Vinocur C., Colombani P., et al. Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children's Cancer Group/Pediatric Oncology Group. J Pediatr Surg 38 (2003) 319-324 discussion 319-24
25. Billmire D., Vinocur C., Rescorla F., Cushing B., London W., Schlatter M., et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 39 (2004) 424-429 discussion 424-9
26. Rogers P.C., Olson T.A., Cullen J.W., Billmire D.F., Marina N., Rescorla F., et al. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study-Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol 22 (2004) 3563-3569
27. Murugaesu N., Schmid P., Dancey G., Agarwal R., Holden L., McNeish I., et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 24 (2006) 4862-4866
28. Munkarah A., Gershenson D.M., Levenback C., Silva E.G., Messing M.J., Morris M., et al. Salvage surgery for chemorefractory ovarian germ cell tumors. Gynecol Oncol 55 (1994) 217-223
29. Li J., Yang W., and Wu X. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients. Gynecol Oncol 105 (2007) 769-775
30. Steele G.S., and Richie JP. Current role of retroperitoneal lymph node dissection in testicular cancer. Oncology (Williston Park) 11 (1997) 717-729 discussion 730-37 passim
31. Rabbani F., Sheinfeld J., Farivar-Mohseni H., Leon A., Rentzepis M.J., Reuter V.E., et al. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 19 (2001) 2020-2025
32. Donohue J.P., Thornhill J.A., Foster R.S., Bihrle R., Rowland R.G., and Einhorn L.H. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol 153 (1995) 85-89
33. Sklar C.A., Mertens A.C., Mitby P., Whitton J., Stovall M., Kasper C., et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 98 (2006) 890-896
34. Pedersen-Bjergaard J., Daugaard G., Hansen S.W., Philip P., Larsen S.O., and Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 338 (1991) 359-363
35. Nichols C.R., Breeden E.S., Loehrer P.J., Williams S.D., and Einhorn L.H. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 85 (1993) 36-40
36. Cooper G.S., Virnig B., Klabunde C.N., Schussler N., Freeman J., and Warren J.L. Use of SEER-Medicare data for measuring cancer surgery. Med Care 40 (2002) IV-43-8
37. Harlan L.C., and Hankey B.F. The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol 21 (2003) 2232-2233